Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.


TSX:MSCL - Post by User

Satellos Bioscience Inc > You want to do what, AGAIN?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by G1945Von Apr 24, 2024 7:13am
34 Views
Post# 36004578

RE:You want to do what, AGAIN?

RE:You want to do what, AGAIN?
Drambuey wrote: Let's see you already rolled this back 20 to 1 and my 100,000 shares became 5,000.  Need $2 to just break even and now you want to pass a resolution to roll this back again WTF I'm so tired of this scam.  $1.4 million paid in salary last year WOW nice gig CROOKS Just exactly how do you justify your compensation with a stock price of .49 you guys are amazing.  $1.4 million for what GREEDY LITTLE PIGS good luck with this scam fellow shareholders I have no faith I will ever see my money but hey I'm glad I contributed to a great life for management and their families who cares about shareholders and their families right as long as management can sleep well at night all is good.  I'm voting no and management  can kiss my .......


"you want to pass a resolution to roll this back again"

Where is this coming from?


G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities